国立研究開発法人国立神経・精神医療研究センター 神経研究所 遺伝子疾患治療研究部

研究業績

原著

2017.9.26現在

2017

  1. Takeuchi F, Komaki H, Yamagata Z, Maruo K, Rodger S, Kirschner J, Kubota T, Kimura E, Takeda S, Gramsch K, Vry J, Bushby K, Lochmüller H, Wada K, Nakamura H: A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: implications of early diagnosis. Neuromuscul Disord. Neuromuscul Disord. 2017 Jul 6. pii: S0960-8966(17)30068-8. doi: 10.1016/j.nmd.2017.06.557. [Epub ahead of print] 
  2. Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T:Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Mol Ther. 2017 Jul 28. pii: S1525-0016(17)30355-6. doi: 10.1016/j.ymthe.2017.07.014.
  3. Ito N, Kii I, Shimizu N, Tanaka H, Takeda S: Direct reprogramming of fibroblasts into skeletal muscle progenitor cells by transcription factors enriched in undifferentiated subpopulation of satellite cells. Sci Rep. 7(1):8097, 2017
  4. Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KR, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T: Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 114: 4213-4218, 2017
  5. Miyagoe-Suzuki Y, Nishiyama T, Nakamura M, Narita A, Takemura F, Masuda S, Minami N, Murayama K,  Komaki H, Goto Y, Takeda S: Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status. Stem Cells Int. 7906843, 9 pages, 2017
  6. Aoki Y, Manzano R, Lee Y, Dafinca R, Aoki M, Douglas AG, Varela MA1 Sathyaprakash C, Scaber J, Barbagallo P, Vader P, Mäger I, Ezzat K, Turner MR, Ito N, Gasco S, Ohbayashi N, El Andaloussi S, Takeda S, Fukuda M, Talbot K, Wood MJ: C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain.2017 Apr 1;140(4):887-897.
  7. Hyzewicz J, Tanihata J, Kuraoka M, Nitahara-Kasahara Y, Beylier T, Ruegg UT, Vater A, Takeda S: Low-Intensity Training and the C5a Complement Antagonist NOX-D21 Rescue the mdx Phenotype through Modulation of Inflammation. Am J Pathol. 2017 Mar 15. pii: S0002-9440(17)30195-5. in press?
  8. Maruyama R, Echigoya Y, Caluseriu O, Aoki Y, Takeda S, Yokota T: Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy. Methods Mol Biol.1565: 201-213, 2017

2016

  1. Matsuzaka Y, Tanihata J, Komaki H, Ishiyama A, Oya Y, Rüegg U, Takeda SI, Hashido K: Characterization and Functional Analysis of Extracellular Vesicles and Muscle-Abundant miRNAs (miR-1, miR-133a, and miR-206) in C2C12 Myocytes and mdx Mice. PLoS One. 11(12):e0167811
  2. Vila MC, Rayavarapu S, Hogarth MW, Van der Meulen JH, Horn A, Defour A, Takeda S, Brown KJ, Hathout Y, Nagaraju K, Jaiswal JK: Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ. 2016 Nov 11. doi: 10.1038/cdd.2016.127.
  3. Suzuki H, Aoki Y, Kameyama T, Saito T, Masuda S, Tanihata J, Nagata T, Mayeda A, Takeda S, Tsukahara T: Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot. Int J Mol Sci. 17: E1722, 2016
  4. Takeuchi F, Komaki H, Nakamura H, Yonemoto N, Kashiwabara K, Kimura E, Takeda S: Trends in steroid therapy for Duchenne muscular dystrophy in Japan. Muscle Nerve. 54: 673-680, 2016
  5. Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, Smith FE, Rufibach L, Cnaan A, Bharucha-Goebel DX, Blamire AM, Bravver E, Carlier PG, Day JW, Díaz-Manera J, Eagle M, Grieben U, Harms M, Jones KJ, Lochmüller H, Mendell JR, Mori-Yoshimura M, Paradas C, Pegoraro E, Pestronk A, Salort-Campana E, Schreiber-Katz O, Semplicini C, Spuler S1, Stojkovic T, Straub V, Takeda S, Rocha CT, Walter MC, Bushby K ; Jain COS Consortium: The Clinical Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet. 2(4):e89, eCollection 2016
  6. Uezumi A, Nakatani M, Ikemoto-Uezumi M, Yamamoto N, Morita M, Yamaguchi A, Yamada H, Kasai T, Masuda S, Narita A, Miyagoe-Suzuki Y, Takeda S, Fukada S, Nishino I, Tsuchida K: Cell-Surface Protein Profiling Identifies Distinctive Markers of Progenitor Cells in Human Skeletal Muscle. Stem Cell Reports. 7: 263-278, 2016
  7. Nakamura A, Fueki N, Shiba N, Motoki H, Miyazaki D, Nishizawa H, Echigoya Y, Yokota T, Aoki Y, Takeda S:Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet. 61: 663-667, 2016
  8. Shimizu R, Ogata K, Tamaura A, Kimura E, Ohata M, Takeshita E, Nakamura H, Takeda S, Komaki H: Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network. BMC Health Serv Res.16:241, 2016
  9. Miskew Nichols B, Aoki Y, Kuraoka M, Lee JJ, Takeda S, Yokota T: Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy. J Vis Exp. 24: 111, 2016
  10. Ito N, Shimizu N, Tanaka H, Takeda S: Enhancement of satellite cell transplantation efficiency by leukemia inhibitory factor. J Neuromuscul Dis. 3: 201-207, 2016
  11. Shimbo M, Kudo T, Hamada M, Jeon H, Imamura Y, Asano K, Okada R, Tsunakawa Y, Mizuno S, Yagami K, Ishikawa C, Li H, Shiga T, Ishida J, Hamada J, Murata K, Ishimaru T, Hashimoto M, Fukamizu A, Yamane M, Ikawa M, Morita H, Shinohara M, Asahara H, Akiyama T, Akiyama N, Sasanuma H, Yoshida N, Zhou R, Wang YY, Ito T, Kokubu Y, Noguchi TA, Ishimine H, Kurisaki A, Shiba D, Mizuno H, Shirakawa M, Ito N, Takeda S, Takahashi S: Ground-based assessment of JAXA mouse habitat cage unit by mouse phenotypic studies. Exp Anim. 65: 175-87, 2016
  12. Kimura K, Morita H, Daimon M, Horio M, Kawata T, Nakao T, Hirokawa M, Kitao R, Watanabe D, Komori T, Nagata T, Takeda S, Komaki H, Segawa K, Nakajima T, Takenaka K, Komuro I: Utility of Cystatin C for Estimating Glomerular Filtration Rate in Patients With Muscular Dystrophy. Int Heart J. 57: 386-8, 2016
  13. Kuraoka M, Kimura E, Nagata T, Okada T, Aoki Y, Tachimori H, Yonemoto N, Imamura M, Takeda S: Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. Am J Pathol. 186:1302-1312, 2016

2015

  1. Ezzat K, Aoki Y, Koo T, McClorey G, Benner L, Coenen-Stass A, O'Donovan L, Lehto T, Garcia-Guerra A, Nordin J, Saleh AF, Behlke M, Morris J, Goyenvalle A, Dugovic B, Leumann C, Gordon S, Gait MJ, El Andaloussi S, Wood MJ:Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Lett. 15: 4364-4373, 2015
  2. Yamaguchi M, Watanabe Y, Ohtani T, Uezumi A, Mikami N, Nakamura M, Sato T, Ikawa M, Hoshino M, Tsuchida K, Miyagoe-Suzuki Y, Tsujikawa K, Takeda S, Yamamoto H, Fukada S: Calcitonin Receptor Signaling Inhibits Muscle Stem Cells from Escaping the Quiescent State and the Niche. Cell Rep. 13: 302-314, 2015
  3. Mizuno S, Yoda M, Shimoda M, Tohmonda T, Okada Y, Toyama Y, Takeda S, Nakamura M, Matsumoto M, Horiuchi K: A Disintegrin and Metalloprotease 10 (ADAM10) Is Indispensable for Maintenance of the Muscle Satellite Cell Pool. J Biol Chem. 290: 28456-28464, 2015
  4. Imamura M, Nakamura A, Mannen H, Takeda S: Characterization of WWP1 protein expression in   skeletal muscle of muscular dystrophy chickens. J Biochem. 159: 171-179, 2015
  5. Domi T, Porrello E, Velardo D, Capotondo A, Biffi A, Tonlorenzi R, Amadio S, Ambrosi A, Miyagoe-Suzuki Y, Takeda S, Ruegg MA, Previtali SC:Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A. Skelet    Muscle. 5: 30, 2015
  6. Kimura K, Morita H, Daimon M, Kawata T, Nakao T, Lee SL, Hirokawa M, Ebihara A, Nakajima T, Ozawa T, Yonemochi Y, Aida I, Motoyoshi Y, Mikata T, Uchida I, Komori T, Kitao R, Nagata T, Takeda S, Komaki H, Segawa K, Takenaka K, Komuro I:Prognostic impact of venous thromboembolism in patients with Duchenne muscular dystrophy: Prospective multicenter 5-year cohort study. Int J Cardiol. 191: 178-180, 2015
  7. Ishii K, Suzuki N, Mabuchi Y, Ito N, Kikura N, Fukada SI, Okano H, Takeda S, Akazawa C: Muscle Satellite Cell Protein Teneurin-4 Regulates Differentiation During Muscle Regeneration. Stem Cells. 33: 3017-3027, 2015
  8. Shiba N, Miyazaki D, Yoshizawa T, Fukushima K, Shiba Y, Inaba Y, Imamura M, Takeda S, Koike K, Nakamura A: Differential roles of MMP-9 in early and late stages of dystrophic muscles in a mouse model of Duchenne muscular dystrophy. Biochim Biophys Acta. 1852: 2170-2182, 2015
  9. Shimizu N, Maruyama T, Yoshikawa N, Matsumiya R, Ma Y, Ito N, Tasaka Y, Kuribara-Souta A, Miyata K, Oike Y, Berger S, Schütz G, Takeda S, Tanaka H: A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodeling. Nat Commun. 6: 6693, 2015
  10. Hayashiji N, Yuasa S, Miyagoe-Suzuki Y, Hara M, Ito N, Hashimoto H, Kusumoto D, Seki T, Tohyama S, Kodaira M, Kunitomi A, Kashimura S, Takei M, Saito Y, Okata S, Egashira T, Endo J, Sasaoka T, Takeda S, Fukuda K: G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy. Nat Commun. 6: 6745, 2015

2014

  1. Yokota T, Miyagoe-Suzuki Y, Ikemoto T, Matsuda R, Takeda S: α1-Syntrophin deficient mice exhibit impaired muscle force recovery after osmotic shock. Muscle Nerve 49: 728-735, 2014
  2. Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyo T, Nishiyama A, Okada H, Takeda S, Okada T: Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10. Hum Mol Genet 23: 3990-4000, 2014
  3. Hathout Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H, Gordish-Dressman H, Cirak S, Bello L, Nagaraju K, Partridge T, Hoffman EP, Takeda S, Mah JK, Henricson E, McDonald C: Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet 23: 6458-6469, 2014
  4. Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda S, Hashido K: Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med 19: 452-458, 2014
  5. Arimura S, Okada T, Tezuka T, Chiyo T, Kasahara Y, Yoshimura T, Motomura M, Yoshida N, Beeson D, Takeda S, Yamanashi Y: Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science 345: 1505-1508, 2014
  6. Mori-Yoshimura M, Hayashi YK, Yonemoto N, Nakamura H, Murata M, Takeda S, Nishino I, Kimura E: Nationwide patient registry for GNE myopathy in Japan. Orphanet J Rare Dis 9: 150, 2014
  7. Ogawa R, Ma Y, Yamaguchi M, Ito T, Watanabe Y, Ohtani T, Murakami S, Uchida S, De Gaspari P, Uezumi A, Nakamura M, Miyagoe-Suzuki Y, Tsujikawa K, Hashimoto N, Braun T, Tanaka T, Takeda S, Yamamoto H, Fukada S: Doublecortin marks a new population of transiently amplifying muscle progenitor cells and is required for myofiber maturation during skeletal muscle regeneration. Development 142: 51-61, 2015
  8. Hayashita-Kinoh H, Yugeta N, Okada H, Nitahara-Kasahara Y, Chiyo T, Okada T, Takeda S: Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther 23: 627-637, 2015
  9. Hyzewicz J, Tanihata J, Kuraoka M, Ito N, Miyagoe-Suzuki Y, Takeda S: Low intensity training of mdx mice reduces carbonylation and increases expression levels of proteins involved in energy metabolism and muscle contraction. Free Radic Biol Med 82: 122-136, 2015
  10. Ohtsuka Y, Kanagawa M, Yu CC, Ito C, Chiyo T, Kobayashi K, Okada T, Takeda S, Toda T: Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression. Sci Rep 5: 8316, 2015
  11. Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T: Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4 :e225, 2015
  12. Nakamura K, Fujii W, Tsuboi M, Tanihata J, Teramoto N, Takeuchi S, Naito K, Yamanouchi K, Nishihara M: Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci Rep 4: 5635, 2014

2013

  1. Kimura K, Takenaka K, Ebihara A, Uno K, Morita H, Nakajima T, Ozawa T, Aida I, Yonemochi Y, Higuchi S, Motoyoshi Y, Mikata T, Uchida I, Ishihara T, Komori T, Kitao R, Nagata T, Takeda S, Yatomi Y, Nagai R, Komuro I: Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy - Prospective multicenter cohort study. Int J Cardiol 168: 1900-1904, 2013
  2. Rayavarapu S, Coley W, Cakir E, Jahnke V, Takeda S, Aoki Y, Grodish-Dressman H, Jaiswal JK, Hoffman EP, Brown KJ, Hathout Y, Nagaraju K: Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol Cell Proteomics 12: 1061-1073, 2013
  3. Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda S: Capsaicin mimics mechanical load-induced intracellular signaling events: Involvement of TRPV1-mediated calcium signaling in induction of skeletal muscle hypertrophy. Channels (Austin) 7: 221-224, 2013
  4. Kanagawa M, Yu CC, Ito C, Fukada SI, Hozoji-Inada M, Chiyo T, Kuga A, Matsuo M, Sato K, Yamaguchi M, Ito T, Ohtsuka Y, Katanosaka Y, Miyagoe-Suzuki Y, Naruse K, Kobayashi K, Okada T, Takeda S, Toda T: Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.Hum Mol Genet 22: 3003-3015, 2013
  5. Oana K, Oma Y, Suo S, Takahashi MP, Nishino I, Takeda S, Ishiura S: Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci Rep 3:2142, 2013
  6. Okada H, Ishibashi H, Hayashita-Kinoh H, Chiyo T, Nitahara-kasahara Y, Baba Y, Watanabe S, Takeda S, Okada T: Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9. Mol Ther Nucleic Acids. 2: e95 2013
  7. Nakamura A, Kobayashi M, Kuraoka M, Yuasa K, Yugeta N, Okada T, Takeda S: Initial Pulmonary Respiration Causes Massive Diaphragm Damage and Hyper-CKemia in Duchenne Muscular Dystrophy Dog. Sci Rep 3:2183, 2013
  8. Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S: Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet. 22: 4914-4928, 2013
  9. Takeuchi F, Yonemoto N, Nakamura H, Shimizu R, Komaki H, Mori-Yoshimura M, Hayashi YK, Nishino I, Kawai M, Kimura E, Takeda S. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. J Neurol 260: 3023-3029, 2013
  10. Ishibashi H, Motohashi H, Kumon M, Yamamoto K, Okada H, Okada T, Seki K: Ultrasound-guided non-surgical embryo collection in the common marmoset. Reproductive Biology 13: 139-144, 2013
  11. Ishibashi H, Motohashi H, Kumon M, Yamamoto K, Okada H, Okada T, Seki K: Efficient embryo transfer in the common marmoset monkey (Callithrix jacchus) with a reduced transfer volume: a non-surgical approach with cryo-preserved late-stage embryos. Biol Reprod 88: 115, 2013
  12. Echigoya Y, Lee J, Rodrigues M, Nagata T, Tanihata J, Nozohourmehrabad A, Panesar D, Miskew B, Aoki Y, Yokota T: Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice. PLoS One 8: e69194, 2013
  13. Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, Ikiz B, Hoffmann L, Koolen M, Nagata T, Papadimitriou D, Nagy P, Mitsumoto H, Kariya S, Wichterle H, Henderson CE, Przedborski S : Necroptosis Drives Motor Neuron Death in Models of Both Sporadic and Familial ALS. Neuron 81:1001-1008, 2014

2012

  1. Ito M, Suzuki Y, Okada T, Fukudome T, Yoshimura T, Masuda A, Takeda S, Krejci E, Ohno K: Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction. Mol Ther 20(7): 1384-1392, 2012
  2. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SMR, Nagaraju K, Hoffman EP, Partridge T, Takeda S: Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109(34): 13763-13768, 2012
  3. Yuasa K, Takeda S, Hijikata T: A conserved regulatory element located far downstream of the gls locus modulates gls expression through chromatin loop formation during myogenesis. FEBS Lett 586(19): 3464-3470, 2012
  4. Yamaguchi M, Ogawa R, Watanabe Y, Uezumi A, Miyagoe-Suzuki Y, Tsujikawa K, Yamamoto H, Takeda S, Fukada S: Calcitonin receptor and Odz4 are differently expressed in Pax7-positive cells during skeletal muscle regeneration. J Mol Histol 43(5): 581-587, 2012
  5. Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S: Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22(5): 306-315, 2012
  6. Relucio J, Menezes MJ, Miyagoe-Suzuki Y, Takeda S, Colognato H: Laminin regulates postnatal oligodendrocyte production by promoting oligodendrocyte progenitor survival in the subventricular zone. Glia 60(10): 1451-1467, 2012
  7. Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda S: Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med. 19(1): 101-106, 2013
  8. Baba Y, Satoh S, Otsu M, Sasaki E, Okada T, Watanabe S: In vitro cell subtype-specific transduction of adeno-associated virus in mouse and marmoset retinal explants culture.Biochimie 94(12): 2716-2722, 2012
  9. Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, Chuah M, Cornetta K, Davies KE, Dickson JG, Duchateau P, Flotte TR, Gaudet D, Gersbach CA, Gilbert R, Glorioso J, Herzog RW, High KA, Huang W, Huard J, Joung JK, Liu D, Liu D, Lochmüller H, Lustig L, Martens J, Massie B, Mavilio F, Mendell JR, Nathwani A, Ponder K, Porteus M, Puymirat J, Samulski J, Takeda S, Thrasher A, Vandendriessche T, Wei Y, Wilson JM, Wilton SD, Wolfe JH, Gao G: Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther 21(2): 266-268, 2013
  10. Ito T, Ogawa R, Uezumi A, Ohtani T, Watanabe Y, Tsujikawa K, Miyagoe-Suzuki Y, Takeda S, Yamamoto H, Fukada SI: Imatinib attenuates dystrophic condition in severe mouse dystrophy and inhibits both proliferation and fibrosis-marker expression in muscle mesenchymal progenitors. Neuromuscul Disord 23(4): 349-356, 2013

2011

  1. Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, Ikeda S:Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet. 20: 1787-1799, 2011
  2. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, Sekiguchi M, Takeda S, Hashido K:Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy. PLoS One. 30; 6(3):e18388, 2011
  3. Takahashi H, Kanesaki H, Igarashi T, Kameya S, Yamaki K, Mizota A, Kudo A, Miyagoe-Suzuki Y, Takeda S, Takahashi H: Reactive gliosis of astrocytes and Müller glial cells in retina of POMGnT1-deficient mice. Mol Cell Neurosci. 47: 119-130, 2011
  4. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP: Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 19: 830-840, 2011
  5. Yamada T, Okaniwa N, Saneyoshi H, Ohkubo A, Seio K, Nagata T, Aoki Y, Takeda S, Sekine M: Synthesis of 2'-O-[2-(N-Methylcarbamoyl)ethyl]ribonucleosides using Oxa-Michael reaction and chemical and biological properties of oligonucleotide derivatives incorporating these modified ribonucleosides. J Org Chem. 76: 3042-3053, 2011
  6. Takano H, Fujii Y, Yugeta N, Takeda S, Wakao Y: Assessment of Left Ventricular Regional Function in Affected and Carrier Dogs with Duchenne Muscular Dystrophy Using Speckle Tracking Echocardiography. BMC Cardiovasc Disord. 11: 23 doi:10.1186/1471-2261-11-23, 2011
  7. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, Connor EM: Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol. 179: 12-22, 2011
  8. Masamizu Y, Okada T, Kawasaki K, Ishibashi H, Yuasa S, Takeda S, Hasegawa I, Nakahara K: Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9. Neuroscience. 193: 249-258, 2011(モデル動物開発部共同研究)
  9. Shin JH, Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-Hosoyama S, Kinoshita K, Chiyo T, Okada H, Okada T, Takeda S: Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther. 18: 910-919, 2011
  10. Kondo H, Ezura Y, Nakamoto T, Hayata T, Notomi T, Sorimachi H, Takeda S, Noda M: MURF1 deficiency suppresses unloading-induced effects on osteoblasts and osteoclasts to lead to bone loss. J Cell Biochem. 112: 3525-3530, 2011
  11. Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu CC, Mori K, Oda T, Kuga A, Kurahashi H, Akman HO, DiMauro S, Kaji R, Yokota T, Takeda S, Toda T : Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature. 478: 127-131, 2011
  12. Fukada S, Yamaguchi M, Kokubo H, Ogawa R, Uezumi A, Yoneda T, Matev MM, Motohashi N, Ito T, Zolkiewska A, Johnson RL, Saga Y, Miyagoe-Suzuki Y, Tsujikawa K, Takeda S, Yamamoto H: Hesr1 and Hesr3 are essential to generate undifferentiated quiescent satellite cells and to maintain satellite cell numbers. Development. 138: 4609-4619, 2011
  13. Wang B, Miyagoe-Suzuki Y, Yada E, Ito N, Nishiyama T, Nakamura M, Ono Y, Motohashi N, Segawa M, Masuda S, Takeda S: Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. PLoS Curr. 10.1371/currents.RRN1274, 2011
  14. Uezumi A, Ito T, Morikawa D, Shimizu N, Yoneda T, Segawa M, Yamaguchi M, Ogawa R, Matev MM, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Tsuchida K, Yamamoto H, Fukada S: Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci, 124: 3654-3664, 2011
  15. Koo T, Okada T, Athanasopoulos T, Foster H, Takeda S, Dickson G: Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med. 13: 497-506, 2011
  16. Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-Hosoyama S, Okada H, Wada-Maeda M, Nakamura A, Okada T, Takeda S: Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy. Mol Ther. 20: 168-177, 2012

2010

  1. Fukada S, Morikawa D, Yamamoto Y, Yoshida T, Sumie N, Yamaguchi M, Ito T, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Yamamoto H:Genetic background affects properties of satellite cells and mdx phenotypes. Am J Pathol. 176: 2414-2424, 2010
  2. Yajima H, Motohashi N, Ono Y, Sato S, Ikeda K, Masuda S, Yada E, Kanesaki H, Miyagoe-Suzuki Y, Takeda S, Kawakami K: Six family genes control the proliferation and differentiation of muscle satellite cells. Exp Cell Res. 316: 2932-2944, 2010
  3. Masamizu Y, Okada T, Ishibashi H, Takeda S, Yuasa S, Nakahara K: Efficient gene transfer into neurons in monkey brain by adeno-associated virus 8. Neuroreport. 21:447-451, 2010
  4. Saito T, Nakamura A, Aoki Y, Yokota T, Okada T, Osawa M, Takeda S: Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient. PLoS One. 5(8). pii: e12239, 2010
  5. Sugita H, Takeda S: Progress in muscular dystrophy research with special emphasis on gene therapy. Proc Jpn Acad Ser B Phys Biol Sci. 86:748-56, 2010
  6. Suzuki N, Mizuno H, Warita H, Takeda S, Itoyama Y, Aoki M:Neuronal NOS is dislocated during muscle atrophy in amyotrophic lateral sclerosis. J Neurol Sci. 294: 95-101, 2010
  7. Kanagawa M, Omori Y , Sato S, Kobayashi K, Miyagoe-Suzuki Y, Takeda S, Endo T, Furukawa T, Toda T : Post-translational maturation of dystroglycan is necessary for pikachurin binding and ribbon synaptic localization. J Biol Chem. 285:31208-31216, 2010
  8. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S:In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther. 18, 1995-2005, 2010
  9. Miyagoe-Suzuki Y, Takeda S: Gene therapy for muscle disease. Exp Cell Res. 316: 3087-3092, 2010
  10. Yokota T, Hoffman E, Takeda S:Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods Mol Biol. 709:299-312, 2011
  11. Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T:The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther. 19:9-15, 2011
  12. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H:Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 13:170-182, 2011
  13. Fukaya M, Kamata A, Hara Y, Tamaki H, Katsumata O, Ito N, Takeda S, Hata Y, Suzuki T, Watanabe M, Harvey RJ, Sakagami H: SynArfGEF is a guanine nucleotide exchange factor for Arf6 and localizes preferentially at post-synaptic specializations of inhibitory synapses. J Neurochem. 116:1122-1137, 2011
  14. Nakamura A, Takeda S:Mammalian models of duchenne muscular dystrophy: pathological characteristics and therapeutic applications. J Biomed Biotechnol. doi: 10.1155/2011:184393.

2009

  1. Chang H, Yoshimoto M, Umeda K, Iwasa T, Mizuno Y, Fukada S, Yamamoto H, Motohashi N, Miyagoe-Suzuki Y, Takeda S, Heike T, Nakahata T : Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells. FASEB J 23: 1907-1919, 2009
  2. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E:Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann Neurol 65: 667-676, 2009
  3. Nakao R, Hirasaka K, Goto J, Ishidoh K, Yamada C, Ohno A, Okumura Y, Nonaka I, Yasutomo K, Baldwin KM, Kominami E, Higashibata A, Nagano K, Tanaka K, Yasui N,Mills EM, Takeda S, Nikawa T : Ubiquitin ligase Cbl-b is a negative regulator for IGF-1 signaling during muscle atrophy caused by unloading. Mol Cell Biol 29: 4798-4811, 2009
  4. Nakamura A, Takeda S : Exon-skipping therapy for Duchenne muscular dystrophy, Neuropathology 29: 494-501, 2009
  5. Katsube K, Ichikawa S, Katsuki Y, Kihara T, Terai M, Lau LF, Tamamura Y, Takeda S, Umezawa : A, Sakamoto K, Yamaguchi A: CCN3 and bone marrow cells. J Cell Commun Signal 3: 135-145, 2009
  6. Okada T, Nonaka-Sarukawa M, Uchibori R, Kinoshita K, Hayashita-Kinoh H, Nitahara-Kasahara Y, Takeda S, Ozawa K: Scalable purification of AAV1 and AAV8 vectors using dual ion-exchange adsorptive membranes. Hum Gene Ther 20: 1013-1021, 2009
  7. Guo P, Cui R, Chang YZ, Wu WS, Qian ZM, Yoshida K, Qiao YT, Takeda S, Duan XL:Hepcidin, an antimicrobial peptide is downregulated in ceruloplasmin-deficient mice. Peptides 30: 262-266, 2009
  8. Cui R, Duan XL, Anderson GJ, Qiao YT, Yu P, Qian ZM, Yoshida K, Takeda S, Guo P, Yang ZL,Chang YZ:Age-dependent expression of hephaestin in the brain of ceruloplasmin-deficient mice. J Trace Elem Med Biol 23: 290-299, 2009
  9. Kobayashi M, Nakamura A, Hasegawa D, Fujita M, Orima H, Takeda S: Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging. Muscle Nerve 40: 815-826, 2009
  10. Matsumoto H, Maruse H, Sasazaki S, Fujiwara A, Takeda S, Ichihara N, Kikuchi T, Mukai F, Mannen H: Expression pattern of WWP1 in muscular dystrophic and normal chickens, J. Poult. Sci 46: 95-99, 2009
  11. Uezumi A, Fukuda S, Yamamoto N, Takeda S, Tsuchida K: Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 12: 143-152, 2010
  12. 武田伸一:筋ジストロフィーの遺伝子治療―エクソン・スキッピングを中心に―. 神経治療学, Vol.26, No.6, 715-718, 2009
  13. 武田伸一:モルフォリノをもちいたDuchenne型筋ジストロフィーの治療. 臨床神経学,49: 856-858, 2009
  14. Masuda-Hirata M, Suzuki A, Amano Y, Yamashita K, Ide M, Yamanaka T, Sakai M, Imamura M, Ohno S. Intracellular polarity protein PAR-1 regulates extracellular laminin assembly by regulating the dystroglycan complex. Genes Cells 14: 835-850, 2009
  15. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, Ozawa K : Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11: 373-381, 2009
  16. Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S. Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med 47:1049-1056, 2009

2008

  1. Tanihata J, Suzuki N, Miyagoe-Suzuki Y, Imaizumi K, Takeda S: Dowmstream utrophin enhancer is required for expression of utrophin in skeletal muscle. J Gene Med. 10: 702-713, 2008
  2. Urasawa N, Wada MR, Machida N, Yuasa K, Shimatsu Y, Wakao Y, Yuasa S, Sano T, Nonaka I, Nakamura A, Takeda S: Selective vacuolar degeneration in dystrophin deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71. Circulation. 117: 2437-2448, 2008
  3. Matsumoto H, Maruse H, Inaba Y, Yoshizawa K, Sasazaki S, Fujiwara A, Nishibori M, Nakamura A, Takeda S, Ichihara N, Kikuchi T, Mukai F, Mannen H: The ubiquitin ligase gene (WWP1) is responsible for the chicken muscular dystrophy. FEBS Lett. 582: 2212-2218, 2008
  4. Hijikata T, Nakamura A, Isokawa K, Imamura M, Yuasa K, Ishikawa R, Kohama K, Takeda S, Yorifuji H: Plectin 1 links intermediate filaments to costameric sarcolemma through {beta}-synemin, {alpha}-dystrobrevin and actin. J Cell Sci. 121: 2062-2074, 2008
  5. Nakamura A, Yoshida K, Fukushima K, Ueda H, Urasawa N, Koyama J, Yazaki Y, Yazaki M, Sakai T, Haruta S, Takeda S, Ikeda S: Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci. 15: 757-763, 2008
  6. Nishiyama A, Ampong BN, Ohshima S, Shin JH, Nakai H, Imamura M, Miyagoe-Suzuki Y, Okada T, Takeda S: Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice. Hum Gene Ther. 19: 719-730, 2008
  7. Sato K, Yokota T, Ichioka S, Shibata M, Takeda S: Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. Acta Myol. 27:30-36, 2008
  8. Motohashi N, Uezumi A, Yada E, Fukada S, Fukushima K, Imaizumi K, Miyagoe-Suzuki Y, Takeda S: Muscle CD31(-) CD45(-) side population cells promote muscle regeneration by stimulating proliferation and migration of myoblasts. Am J Pathol. 173: 781-791, 2008
  9. Katsumata O, Honma T, Sanda M, Kamata A, Takeda S, Kondo H, Sakagami H: Predominant localization of EFA6A, a guanine nucleotide exchange factor for ARF6, at the perisynaptic photoreceptor processes. Brain Res. 1234:44-49, 2008
  10. Yuasa K, Hagiwara Y, Ando M, Nakamura A, Takeda S, Hijikata T: MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy. Cell Struct Funct. 33: 163-169, 2008
  11. Segawa M, Fukada S, Yamamoto Y, Yahagi H, Kanematsu M, Sato M, Ito T, Uezumi A, Hayashi S, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Yamamoto H: Suppression of macrophage functions impairs skeletal muscle regeneration with severe fibrosis. Exp Cell Res. 314: 3232-3244, 2008
  12. Ohshima S, Shin JH, Yuasa K, Nishiyama A, Kira J, Okada T, Takeda S: Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther. 17: 73-80, 2009
  13. Sekiguchi M, Zushida K, Yoshida M, Maekawa M, Kamichi S, Yoshida M, Sahara Y, Yuasa S, Takeda S, Wada K: A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain. 132: 124-135, 2009
  14. Kanagawa M, Nishimoto A, Chiyonobu T, Takeda S, Miyagoe-Suzuki Y, Wang F, Fujikake N, Taniguchi M, Lu Z, Tachikawa M, Nagai Y, Tashiro F, Miyazaki J, Tajima Y, Takeda S, Endo T, Kobayashi K, Campbell KP, Toda T: Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum Mol Genet. 18: 621-31, 2009
  15. Miyagoe-Suzuki Y, Masubuchi N, Miyamoto K, Wada MR, Yuasa S, Saito F, Matsumura K, Kanesaki H, Kudo A, Manya H, Endo T, Takeda S: Reduced proliferative activity of primary POMGnT1-null myoblasts in vitro. Mech Dev. 126: 107-116, 2009
  16. Miyazaki D, Yoshida K, Fukushima K, Nakamura A, Suzuki K, Sato T, Takeda S, Ikeda S: Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene. J Hum Genet. 54: 127-130, 2009
  17. Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP: A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66: 32-38, 2009
  18. Nonaka-Sarukawa M, Okada T, Ito T, Yamamoto K, Yoshioka T, Nomoto T, Hojo Y, Shimpo M, Urabe M, Mizukami H, Kume A, Ikeda U, Shimada K, Ozawa K: Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. J Gene Med. 10: 368-374, 2008
  19. Liu Y, Okada T, Shimazaki K, Sheykholeslami K, Nomoto T, Muramatsu S, Mizukami H, Kume A, Xiao S, Ichimura K, Ozawa K: Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea. Mol Ther. 16: 474-480, 2008
  20. Nomoto T, Okada T, Shimazaki K, Yoshioka T, Nonaka-Sarukawa M, Ito T, Takeuchi K, Katsura KI, Mizukami H, Kume A, Ookawara S, Ikeda U, Katayama Y, Ozawa K: Systemic delivery of IL-10 by an AAV vector prevents vascular remodeling and end-organ damage in stroke-prone spontaneously hypertensive rat. Gene Ther. 16: 383-391, 2009
  21. 北秀樹, 中村昭則, 市川慎一, 八幡由美子, 小林正典, 弓削田直子, 武田伸一:筋ジストロフィー犬(CXMDJ)の飼育管理における胃内カテーテル投与法およびハンド・フィーディング法の有用性,実験動物技術43: 17-24, 2008

2007

  1. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K, Takahashi T, Goto M, Mikami Y, Yasuda N, Akazawa H, Uezumi A, Takeda S, Komuro I: Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol. Jan 29;176(3): 329-41, 2007
  2. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda S, Ikeda SI: Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet Disord Jun 28;8: 54, 2007
  3. Suzuki N, Motohashi N, Uezumi A, Fukada SI, Yoshimura T, Itoyama Y, Aoki M, Miyagoe-Suzuki Y, Takeda S: NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest. Sep;117(9): 2468-76, 2007
  4. Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, Nakamura A, Hijikata T, Miyagoe-Suzuki Y,. Takeda S: Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.Gene Ther. Sep;14(17): 1249-60, 2007
  5. Fukada S, Uezumi A, Ikemoto M, Masuda S, Segawa M, Tanimura N, Yamamoto H, Miyagoe-Suzuki Y, Takeda S: Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem Cells Oct;25(10): 2448-59, 2007
  6. Hirasaka K, Kohno S, Goto J, Furochi H, Mawatari K, Harada N, Hosaka T, Nakaya Y, Ishidoh K, Obata T, Ebina Y, Gu H, Takeda S, Kishi K, Nikawa T: Deficiency of Cbl-b gene enhances infiltration and activation of macrophages in adipose tissue and causes peripheral insulin resistance in mice. Diabetes. Oct;56(10): 2511-22, 2007
  7. Ikemoto M, Fukada S, Uezumi A, Masuda S, Miyoshi H, Yamamoto H, Wada MR, Masubuchi N, Miyagoe-Suzuki Y, Takeda S: Autologous transplantation of SM/C-2.6(+) satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Mol Ther. Dec;15(12): 2178-85, 2007
  8. Fukada S, Yamamoto Y, Segawa M, Sakamoto K, Nakajima M, Sato M, Morikawa D, Uezumi A, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Yamamoto H: CD90-positive cells, an additional cell population, produce laminin <alpha>2 upon transplantation to dy3k/dy3k mice. Exp Cell Res. Jan 1;314(1): 193-203, 2008
  9. Yuasa K, Nakamura A, Hijikata T, Takeda S: Dystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscle. BMC Musculoskelet Disord. Jan 9;9: 1, 2008
  10. Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K: Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J. Feb;22(2): 477-87, 2008
  11. Ideno J, Mizukami H, Kakehashi A, Saito Y, Okada T, Urabe M, Kume A, Kuroki M, Kawakami M, Ishibashi S, Ozawa K: Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med Jan;19 (1): 75-79, 2007
  12. Takei Y, Mizukami H, Saga Y, Yoshimura I, Hasumi Y, Takayama T, Kohno T, Matsushita T, Okada T, Kume A, Suzuki M, Ozawa K: Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer Jan 15;120(2): 278-84, 2007
  13. Nakata M, Okada T, Ozawa K, Yada T: Resistin induces insulin resistance in pancreatic islets to impair glucose-induced insulin release. Biochem Biophys Res Commun Feb 23;353(4): 1046-51, 2007
  14. Liu Y, Okada T, Nomoto T, Ke X, Kume A, Ozawa K, Xiao S: Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. Exp Mol Med Apr 30;39(2): 170-75, 2007
  15. Ito T, Okada T, Miyashita H, Nomoto T, Nonaka-Sarukawa M, Uchibori R, Maeda Y, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Shimada K, Ozawa K:Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res Sep 28; 101(7): 734-41,2007
  16. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Sakata Y, Shimada K, Ozawa K: Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension Sep;50(3): 531-36, 2007

2006

  1. Uezumi A, Ojima K, Ikemoto M, Masuda S, Miyagoe-Suzuki Y, Takeda S : Functional heterogeneity of side population cells in skeletal muscle Biochem Biophys Res Commun, 341:864-73, 2006
  2. Suzue N, Nikawa T, Onishi Y, Yamada C, Hirasaka K, Ogawa T, Furochi H, Kosaka H, Ishidoh K,
  3. Gu H, Takeda S, Ishimaru N, Hayashi Y, Yamamoto H, Kishi K, Yasui N:Ubiquitin ligase Cbl-b down-regulate bone formation through suppression of OGF-1 signaling in osteblasts during denervation. J Bone Miner Res. 2006 May; 21(5):722-34.
  4. Yokota T, Lu QL, Morgan JE, Davies KE, Fisher R, Takeda S, Partridge TA: Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J Cell Sci. 2006 Jul 1; 119(Pt 13): 2679-87.
  5. Shiga K, Yoshioka H, Matsumiya T, Kimura I, Takeda S, Imamura M:zeta-Sarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of the sarcoglycan complex. Exp Cell Res. 2006 Jul 1;312(11):2083-92. Epub 2006 Apr 25.
  6. Pramono ZA, Lai PS, Tan CL, Takeda S, Yee WC:Identification and characterization of a novel human dysferlin transcript: dysferlin_v1.Hum Genet. 2006 Oct;120(3):410-9.
  7. Yugeta N, Urasawa N, Fujii Y, Yoshimura M, Yuasa K, Nakamura A, Wada M, Nakura M, Shimatsu Y, Tomohiro M, Takahashi A, Machida N, Wakao Y, Takeda S: Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies BMC Cardiovasc Disord. 2006 Dec 4;6:47.
  8. Suzuki N, Miyagoe-Suzuki Y, Takeda S: Gene Therapy for Duchenne Muscular Dystrophy Future Neurology, Jan 2007, Vol.2(1), 87-96.
  9. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K, Takahashi T, Goto M, Mikami Y, Yasuda N, Akazawa H, Uezumi A, Takeda S, Komuro I: Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol. 2007 Jan 29;176(3):329-41.
  10. Hagiwara Y, Fujita M, Imamura M, Noguchi S, Sasaoka T: Caveolin-3 deficiency decreases the gene expression level of osteopontin in mdx mouse skeletal muscle. Acta Myol. 25, 53-61, 2006

著書

2017.4.25現在

2016

  1. 青木吉嗣, 武田伸一:Duchenne型筋ジストロフィーとエクソン・スキップ治療.  EBMに基づく脳神経疾患の基本治療指針 第4版.編集 田村晃,松谷雅生,清水輝夫,辻貞俊,塩川芳昭,成田善孝,株式会社メディカルビュー社,東京,pp688-694, 2016
  2. 齊藤 崇,武田伸一:デュシェンヌ型筋ジストロフィーに対するアンチセンス核酸医薬の臨床試験.核酸医薬の創製と応用展開,監修:和田猛,シーエムシー出版,東京,pp247-257, 2016
  3. Takeda S, Nagata T: Translational Research on DMD in Japan. Translational Research in Muscular Dystrophy, Springer, Tokyo, pp189-199, 2016
  4. Miyagoe-Suzuki Y, Takeda S: Stem Cell-Based Therapy for Duchenne Muscular Dystrophy. Translational Research in Muscular Dystrophy, Translational Research in Muscular Dystrophy, Springer, Tokyo, pp123-135, 2016
  5. 青木吉嗣, 武田伸一:デュシェンヌ型筋ジストロフィーに対するエクソン53スキップ薬開発の試み.Annual Review 2016神経,中外医学社,東京,pp75-81, 2016

2015

  1. 鈴木良次,鈴木友子,武田伸一:難治性筋疾患に対する細胞移植治療法の開発.再生医療-新たな医療を求めて-,日本臨牀,73: 311-315, 2015
  2. 青木吉嗣, 武田伸一:筋収縮機構と遺伝性筋疾患.別冊 日本臨牀 骨格筋症候群第2版(上), 日本臨床社, 大阪, 9-14, 2015

2013

  1. 永田哲也, 武田伸一:エクソン・スキップ.筋疾患診療ハンドブック,中外医学社,pp187-191, 2013
  2. Okada T: Efficient AAV vector production system: Towards gene therapy for Duchenne muscular dystrophy. In Gene Therapy - Tools and Potential Applications (ed. by Francisco Martin), InTech, pp429-440, 2013

2012

  1. Miyagoe-Suzuki Y, Fukada S, Takeda S: Muscle Satellite Cells and Duchenne Muscular Dystrophy. Muscular dystrophy, InTech-Open Access Company, Croatia, pp333-348, 2012
  2. Okada T: Efficient AAV vector production system: Towards gene therapy for Duchenne muscular dystrophy. In Gene Therapy - Tools and Potential Applications (ed. by Francisco Martin), InTech, Croatia, pp429-449, 2012
  3. 木村 円, 武田伸一:筋ジストロフィー(ジストロフィノパチー),今日の神経疾患治療指針第2版,医学書院,pp776-779, 2012

2011

  1. Okada T, Takeda S: Progress and Challenges in AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy. Viral Gene Therapy (ed. by Ke Xu), InTech, Croatia, pp225-240, 2011
  2. Nagata T, Takeda S: The frontier of antisense oligonucleotide induced therapy (ed. by Takeda S). Fifty years of neuromuscular disorder research after discovery of creatine kinase as a diagnostic marker of muscular dystrophy, IGAKU-SHOIN Ltd., Japan, pp56-67, 2011
  3. Yokota T, Takeda S: Antisense oligo-mediated multiple skipping in a dog model of duchenne muscular dystrophy (ed. by Duan D). Muscle gene therapy, Methods and Protocols, Methods in Molecular Biology, Springer Science+Business Media, USA, pp299-312, 2011
  4. 青木吉嗣,武田伸一:デュシェンヌ型筋ジストロフィーに対するエクソン・スキップ療法.神経疾患最新の治療2012-2014,南江堂,東京pp48-53, 2012

2010

  1. Miyagoe-Suzuki Y, Takeda S: Mechanobiology in skeletal muscle: conversion of mechanical information into molecular signal. Mechanosensing Biology (ed.Masaki Noda), Springer Japan, pp1-219, 2010
  2. Okada T, Takeda S: Advances in molecular therapy research on dystrophin-deficient muscular dystrophy. In, Gene Therapy and Regulation (ed. by Roger.Bertolotti), World Scientific, NJ, 5(1), pp113-123, 2010
  3. 鈴木友子,武田伸一:筋ジストロフィーモデルマウス.完全版マウス・ラット疾患モデル活用ハンドブック,株式会社羊土社,pp378-393, 2011
  4. 鈴木友子,遠藤玉夫:第11節POMGnT1.モデル動物利用マニュアル 生物機能モデルと新しいリソース・、リサーチツール,株式会社エル・アイ・シー,pp368-374, 2011
  5. 青木吉嗣, 本橋裕子, 中村治雅, 小牧宏文, 永田哲也, 武田伸一:デュシェンヌ型筋ジストロフィーのお子さんを持つ家族のためのガイド(監修:武田伸一). 独立行政法人国立精神・神経医療研究センター研究グループ, 東京, pp 1-54, 2011

2009

  1. Ito N & Miyagoe-Suzuki Y : Neuronal NOS as a regulator of muscle mass. Muscle Cell Physiology, pp97-107, 2009, Osaka University Press.
  2. 鈴木友子,武田伸一:骨格筋. 炎症・再生医学事典,朝倉書店, pp453-456, 2009
  3. 中村昭則, 武田伸一: 12-28ジストロフィン異常症.内科学症例図説,朝倉書店, pp 575-577, 2009
  4. 中村昭則,武田伸一:Duchenne型筋ジストロフィー. TOPICS 治療研究の現状,埜中征哉監修,小牧宏文編集,小児筋疾患診療ハンドブック,診断と治療社,pp93-98, 2009
  5. 青木吉嗣,武田伸一:筋ジストロフィー 多発筋炎. 研修医のための神経内科診療, 新興医学出版社, pp248-252, 2010

2008

  1. Miyagoe-Suzuki Y, Uezumi A, Takeda S: Side population (SP) cells and skeletal muscle differentiation.Recent Advances of Skeletal Muscle Differentiation, Editors: Tsuchida K and Takeda S. Research Signpost , Kerala, India, pp 61-78, 2008
  2. 中村昭則,武田伸一:筋ジストロフィーのexon skipping療法の試み.Annual Review 神経 中外医学社, pp 241-251, 2009
  3. 青木吉嗣,武田伸一:筋ジストロフィー.神経疾患最新の治療2009-2011, 南江堂, pp 309-311 2009-2011

2007

  1. Miyagoe-Suzuki Y, Uezumi A, Takeda S: Side Population (SP) cells and skeletal muscle differentiation. Recent advances of skeletal muscle differentiation, Research Signpost, 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India, 2007
  2. 武田伸一: 筋ジストロフィー治療法研究の進歩. こころの健康科学研究の現状と課題 Ⅱ.3.3: 315-327, 2007
  3. 武田伸一: ジストロフィン欠損における新たな分子病態. 小児神経学の進歩 第36集: 132-138, 2007

2006

  1. 鈴木友子,武田伸一:筋ジストロフィーの治療を目指して先進・脳神経科学,監修:高坂新一,編著:中村俊,培風館:174-187, 2006

総説

2017.9.26現在

2017

  1. 武田伸一:巻頭言 ~筋肉研究が医学/生物学位もたらすパラダイム・シフト~.CLINICAL -CALCIUM,特集筋肉研究の最前線,特集ゲスト編集 武田伸一,27: 7-8, 2017 

2016

  1. 武田伸一:トランスレーショナル・メディカルセンターにおける医師主導治験の実際.臨床評価,44, 695-700, 2017
  2. 伊藤尚基谷端淳武田伸一:骨格筋の表現型解析.実験医学別冊マウス表現型解析スタンダード,169-176, 2016
  3. 竹村英子鈴木友子武田伸一:筋ジストロフィーの遺伝子治療,細胞移植治療の最前線.小児内科,東京医学社,48: 12, 1910-1914, 2016
  4. 宮武正太青木吉嗣武田伸一:デュシェンヌ型筋ジストロフィーに対するエクソンスキップ治療 ―有効性と安全性を併せもつモルフォリノ核酸の開発に向けて.実験医学,羊土社, 東京, 34: 19, 3151-3158, 2016
  5. 谷端淳武田伸一:筋ジストロフィー病態における細胞内Ca2+動態.CLINICAL CALCIUM,26: 27(1677)-33(1683), 2016
  6. Tanihata J, Takeda S: Changes in cytosolic Ca2+dynamics in the sarcoplasmic reticulum associated with the pathology of Duchenne muscular dystrophy. JPFSM. 5: 309-312, 2016
  7. 青木吉嗣,武田伸一:Duchenne型筋ジストロフィーに対するエクソン51および53スキップ薬開発の現状.週刊医学のあゆみ,259: 5-10, 2016
  8. Nitahara-Kasahara Y, Takeda S, Okada T:Inflammatory predisposition predicts disease phenotypes in muscular dystrophy. Inflammation and Regeneration. 36: 14, 2016
  9. Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y: Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther. 10: 2745-2758, 2016
  10. Kuraoka M, Takeda S: Serum osteopontin as a novel biomarker for muscle regeneration in Duchenne muscular dystrophy. Atlas of Science. July 1, 2016
  11. Shimizu-Motohashi Y, Miyatake S, Komaki H, Takeda S, Aoki Y: Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res. 8: 2471-2489, 2016
  12. 伊藤尚基,武田伸一:メカニカルストレスと骨格筋肥大・筋萎縮.メカノバイオロジーからメカノメディシンへ,週刊医学のあゆみ,257: 979-984, 2016
  13. 青木吉嗣:素顔のニューロサイエンティスト Matthew JA Wood. Clinical Neuroscience別冊,中外医学社,34: 7, 2016
  14. 青木吉嗣,武田伸一:Duchenne型筋ジストロフィーに対するエクソンスキップ薬開発の試み.Clinical Neuroscience, 3月号 筋ジストロフィー up to date. 中外医学社, 34: 355-358, 2016
  15. 中村昭則,武田伸一:骨格筋機能―発達と加齢.Clinical Neuroscience, 3月号 筋ジストロフィー up to date. 中外医学社, 34: 273-276, 2016
  16. 荒木敏之,畠山英之,武田伸一:疾患特異的iPS細胞を活用した筋疾患研究.実験医学,34: 4, 535-539, 2016

2015

  1. Aoki Y, Douglas AG, Wood MJ: Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment? Neurodegener Dis Manag. 5: 93-95, 2015
  2. Hyzewicz J, Ruegg U, Takeda S: Comparison of Experimental Protocols of Physical Exercise for mdx Miceand Duchenne Muscular Dystrophy Patients. J Neuromuscul Dis. 2: 325-342, 2015
  3. 和田英治,谷端 淳,松田良一,武田伸一:筋ジストロフィーの合併症と最新の治療法.THE BONE 秋号,特集「筋と骨」,メディカルレビュー社,Vol.29, No.3, 93-97, 2015
  4. 武田伸一,鈴木友子:筋ジストロフィーの再生医療.再生医療,14, 3: 26-39,2015
  5. 成田麻子,武田伸一:ヒト多能性幹細胞を用いたDuchenne型筋ジストロフィーの細胞移植治療法の開発.iPS細胞研究最前線―疾患モデルから臓器再生まで,別冊・医学のあゆみ,10:63-68,2015
  6. Nichols B, Takeda S, Yokota T: Nonmechanical Roles of Dystrophin and Associated Proteins in Exercise, Neuromuscular Junctions, and Brains. Brain Sci. 5:275-298, 2015
  7. Ito N, Takeda S:Role of Ca2+ signaling in skeletal muscle hypertrophy and atrophy. J Phys Fitness Sports Med, 4: 171-176, 2015 DOI: 10.7600/jpfsm.4.171.

2014

  1. 齊藤 崇,武田伸一:第7章 各疾患における遺伝子治療,遺伝子診断の現状と今後有望な開発ターゲットの考察 第18節 Duchenne型筋ジストロフィーに対するアンチセンス医薬品を用いたエクソン・スキップ療法.遺伝子治療・診断の最先端技術と新しい医薬品・診断薬の開発,387-390, 2014
  2. 鈴木麻衣子,永田哲也,武田伸一:医薬品関連・薬事戦略相談を受けて.PHARMSTAGE, 14: 19-23, 2014
  3. 成田麻子,武田伸一:ヒト多能性幹細胞を用いたDuchenne型筋ジストロフィーの細胞移植治療法の開発,週刊医学のあゆみ,251: 513-518, 2014
  4. 永田哲也,武田伸一:筋ジストロフィー DMDへのエクソン・スキップ療法.難病と在宅ケア,20: 43-46, 2014
  5. 伊藤尚基,鈴木友子,武田伸一:骨格筋神経型一酸化窒素合成酵素により誘起されるCa2+シグナルが筋肥大を促進する.日本生理人類学会誌,19(3) : 179-183, 2014
  6. Nitahara-Kasahara Y, Takeda S, Okada T: Cell therapeutic approaches using multipotent mesencymal stromal cells for muscular dystrophy. Inflammation and Regeneration, 34(4): 198-205, 2014
  7. 鈴木友子,武田伸一:疾患特異的iPS細胞を活用した筋疾患治療研究.遺伝子医学MOOK,27: 77-81, 2015
  8. Kimura E, Nakamura H, Mitsuhashi S, Takeuchi F, Mori-Yoshimura M, Shimizu R, Komaki H, Hayashi YK, Nishino I, Kawai M, Takeda S: The infrastructure for the clinical research of muscular dystrophies: Remudy and MDCTN. Rinsho Shinkeigaku. 54: 1069-1070, 2014
  9. Watanabe Y, Miyagoe-Suzuki Y: Possibility of small-molecule-based pharmacotherapy for sarcopenia. J Phys Fitness Sports Med, 4 (1): 73-82, 2015

2013

  1. 伊藤尚基,武田伸一:神経型一酸化窒素により誘起されるTRPV1を介したCa2+シグナルは骨格筋肥大を促進する.月刊実験医学 31: 901-904, 2013
  2. 伊藤尚基,鈴木友子,武田伸一:筋疾患へのサテライト細胞の利用.生体の科学 64: 162-167, 2013
  3. Ito N, Miyagoe-Suzuki Y, Takeda S: Molecular basis of muscle hypertrophy and atrophy: potential therapy for muscular dystrophy. J Sports Med Phys Fitness 2: 179-184, 201
  4. Saito T, Ishigaki K, Murakami T, Sato T, Kajino S, Takeda S, Osawa M: Identification of a Duplication Breakpoint in the DMD Gene Using Array Comparative Genomic Hybridization. Journal of Tokyo Women's Medical College 83: E20-E24. 2013
  5. 齊藤崇,武田伸一:選択的スプライシングを調節するアンチセンス医薬品の開発について.医薬品医療機器レギュラトリーサイエンス 45: 23-32, 2014
  6. Okada T, Takeda S: Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy. Pharmaceuticals (Basel) 6: 813-836.2013

2012

  1. 齊藤 崇,永田哲也,青木吉嗣,谷端 淳,増田 智,本橋裕子,横田俊文,武田伸一:患者由来細胞を用いたデュシェンヌ型筋ジストロフィーに対するエクソン・スキッピング治療の開発. 臨床薬理 43 (2): 83-94, 2012
  2. 齊藤 崇,武田伸一:Duchenne型筋ジストロフィーに対するエクソン・スキップ療法. 神経内科 76 (4): 355-360, 2012
  3. 青木吉嗣,武田伸一:筋ジストロフィー犬とエクソンスキップ治療の最前線.遺伝子医学MOOK22号, メディカルドゥ, 大阪, 2012
  4. Aoki Y, Nagata T, Takeda S: New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy. International Journal of Advanced Computer Science, 16: 521-526, 2012
  5. 伊藤尚基, 武田伸一:nNOSにより誘起される陽イオンチャネルTRPV1を介したCa2+シグナルは骨格筋の肥大を促進する.ライフサイエンス新着論文レビュー, 2012
  6. 倉岡睦季,武田伸一:Duchenne型筋ジストロフィーに対する治療の展望.Bio Clinica27:32-36, 北隆館, 2012

2011

  1. 武田伸一:特集に寄せて―骨格筋研究の見通し.生体の科学, 62: 78, 2011
  2. 青木吉嗣, 武田伸一:デュシェンヌ型筋ジストロフィーに対するエクソンスキップ療法. 生体の科学, 62: 128-33, 2011
  3. 青木吉嗣,鈴木友子:筋痛の診断と治療.Monthly Book Orthopaedics. 24:143-152, 2011
  4. Aoki Y, Shimizu Y, Nagata T, Takeda S: Challenges to oligonucleotides-based therapeutics, especially with regards to exon 51 skipping for Duchenne muscular dystrophy. Modeling, Simulation and Applied Optimization (ICMSAO). 2011.5775520.
  5. 永田哲也,武田伸一:筋ジストロフィーの新しい治療戦略.神経内科,74: 339-346, 2011
  6. 武田伸一:神経筋疾患研究の将来の展望.学術の動向,16:73-77, 2011
  7. Nakamura A, Takeda S: Exon-skipping therapy for Duchenne muscular dystrophy. Lancet, 378: 546-547, 2011
  8. 西山尚志,武田伸一:iPS細胞と筋ジストロフィー―筋ジストロフィーの細胞移植治療の実現化を目指して.BRAIN and NERVE, 64: 39-46, 2012
  9. Aoki Y, Nagata T, Shimizu-Motohashi Y, Takeda S: Antisense oligonucleotide-mediated exon 51-skipping therapy for Duchenne muscular dystrophy. International Journal of Advanced Computer Science, Vol. 1, No. 5, 209-214, 2011
  10. 武田伸一:デュシェンヌ型に対するエクソン・スキップ治療.臨床神経,51:914-916, 2012
  11. 木村 円,中村治雅,林 由紀子,西野一三,川井 充,武田伸一:日本におけるデュシェンヌ型筋ジストロフィー患者登録システム―国際的な希少疾病データベースモデルとしてのRemudyの取り組み.生体の科学,63: 62-68, 2012

2010

  1. 清水裕子,武田伸一:筋ジストロフィーの分子治療.-遺伝子診断の進歩とゲノム治療の展望―,遺伝子診療学(第2版),68:8, 650-653, 2010
  2. 青木吉嗣,武田伸一:デュシェンヌ型筋ジストロフィーのエクソン・スキッピング療法.神経難病の最新治療法[第1部],難病と在宅ケア,16:6, 6-9, 2010
  3. 鈴木友子,武田伸一:筋ジストロフィー.総合リハビリテーション,39:1, 25-29, 2011
  4. 小林正典,武田伸一:筋ジストロフィーのエクソン・スキップによる分子治療.医学のあゆみ,237:3, 251-257, 2011
  5. 岡田尚巳:筋疾患の遺伝子治療. BIO Clinica , 26:4, 28-32, 2011
  6. 武田伸一:筋ジストロフィーの新しい治療戦略. 神経治療学, 27:6, 788-790, 2010
  7. Nagata T, Takeda S:Antisense Oligos for Muscular Dystrophy. Rinsho Shinkeigaku.50:843-843,2010

2009

  1. 矢田英理香,武田伸一:iPS細胞を用いた筋ジストロフィー治療の展望. 難病と在宅ケア, vol.15, No.1, 24-27, 2009
  2. 永田哲也,武田伸一:筋ジストロフィーとエクソン・スキッピング. 生物の科学遺伝,Vol.63, No.5, 84-89,2009
  3. 鈴木友子,武田伸一:筋ジストロフィーに対する先端治療法の開発. ゲノム医学,Vol.9,No.3,195-198, 2009

2008

  1. 中村昭則,武田伸一:心筋症 病態生理 筋ジストロフィーの最新知見.治療学 ライフサイエンス出版 42: 42-46, 2008
  2. 深田宗一朗, 鈴木友子, 武田伸一: 筋ジストロフィーの治療とケア 筋衛星細胞の維持 活性化と自己複製の制御機構. 難病と在宅ケア 14: 50-52, 2008
  3. 吉村まどか, 武田伸一: 筋ジストロフィー・ミオパチー.新版 処方計画法 総合臨床   57: 606-608, 2008
  4. 笠原優子, 岡田尚巳,武田伸一: ウイルスベクターを用いた筋ジストロフィーの治療法開発. 医学のあゆみ 226: 379-383, 2008
  5. 齊藤崇, 武田伸一: 高齢者の筋ジストロフィー/多発性筋炎のケア.高齢者神経疾患のトータルマネージメント Modern Physician 28: 656-660, 2008
  6. 小林正典, 武田伸一: 筋ジストロフィーの遺伝子治療.総合リハビリテーション36: 1043-1049, 2008
  7. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, Kikuchi Y, Ito T, Okada T, Urabe M, Mizukami H, Kume A: Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 30: 121-127, 2008
  8. Okada T, Ozawa K: Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy. Front Biosci. 13: 1887-1891, 2008
  9. Okada T, Ozawa K: Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy. Front Biosci. 13: 1887-1891, 2008

2007

  1. 武田伸一: 国立精神・神経センターにおける筋ジストロフィー研究の成果. 週刊社会保障, No.2426: 31, 2007
  2. Suzuki N, Miyagoe-Suzuk Y, Takeda S: Gene therapy for Duchenne muscular dystrophy. Future Neurology 2(1): 87-96, 2007
  3. 岡田尚巳, 武田伸一:遺伝子導入「筋ジストロフィー 現在と未来」Clinical Neuroscience 26(2): 204-206, 2008
  4. 湯浅勝敏, 土方貴雄, 武田伸一: 筋ジストロフィーの遺伝子治療における骨格筋への遺伝子デリバリー. Drug Delivery System 22(2): 140-147, 2007
  5. 西山章代, 武田伸一: 骨格筋へのin vivo 遺伝子導入. バイオテクノロジージャーナル 7: 183-187, 2007
  6. 本橋紀夫, 武田伸一: 筋肉の再生. THE BONE 21(4): 61-64, 2007
  7. 辛鎮洪, 武田伸一: 筋ジストロフィーの治療戦略. BRAIN and NERVE 59(4): 415-424, 2007
  8. 吉田幹晴:ジストロフィン複合体におけるタンパク質間相互作用. 生体の科学 58(5): 440-441, 2007
  9. 吉田幹晴:サルコグリカノパチー. Clinical Neuroscience 26(2): 152-153, 2008
  10. Okada T, Ozawa K: Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy. Front Biosci 13: 1887-1891, 2008

2006

  1. 松尾雅文、武田伸一 : 最近分かった筋ジストロフィーの病態と治療. 脳と発達 38(2) : 129-131, 2006
  2. 横田俊文、武田伸一 : 筋ジストロフィーに対する遺伝子治療の試み. 医学のあゆみ 216(10) : 743-747, 2006
  3. 上住聡芳,鈴木直輝,武田伸一:筋疾患の病態と診断, 治療戦略の最前線 筋ジストロフィーの再生医療. 小児科診療・第69巻・4号:570-574, 2006
  4. 西山章代,武田伸一:筋ジストロフィーのモデル動物と遺伝子治療. Current Insights in Neurological Science VOL.14 No.1: 8-9, 2006
  5. 西山章代,武田伸一:骨格筋組織への in vivo遺伝子導入 BIOバイオテクノロジージャーナル VOl.7 No.2, 3-4 : 183-187, 2006

page
top